Sonnet Biotherapeutics to Merge with Hyperliquid Strategies as HYPE Token Purchase Plans Backed by Up to $1 Billion

COINOTAG News, December 2 — Market sources report that Sonnet Biotherapeutics has obtained shareholder approval to merge with Hyperliquid Strategies. The move marks a notable collaboration between a biotech entity and a liquidity-focused platform within today’s cross-market deal activity, aligning strategic assets and capital formation in a changing digital asset landscape.

Earlier disclosures indicated that Hyperliquid Strategies intends to raise up to $1 billion to fund an acquisition of HYPE, the platform’s flagship token/instrument. Investors should watch for formal filings and market reaction as the merger progresses, noting the potential implications for liquidity provisioning and tokenized asset markets.